HONG KONG – Researchers from the Riken Center for Life Science Technologies in Japan said they have gained new insights into the role of a chemokine protein in the enhancement of stem cell pluripotency, an improved understanding that could lead to the development of more stable and clinically useful stem cells.
SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd., of Lianyungang and Shanghai, won FDA approval for its third cancer drug, oxaliplatin, an alkylating agent used to treat colorectal cancer, as the firm's pioneering efforts as a Chinese pharma to pass the hurdles of developed markets begin to pay off.
SHANGHAI – Six Chinese government agencies with authority over health matters, including the CFDA and the National Health and Family Planning Commission, have issued a joint opinion on pediatric drugs in an attempt to address the problem of medicine safety for children in China.
SHANGHAI – Another month, another announcement for Lee's Pharmaceuticals Ltd., of Hong Kong, as it has been slowly but surely building a successful biotech business and developing and commercializing products for the China market.
TIANJIN, China – Among the country's plan to boost its biopharmaceutical sector, a focus on developing antibodies is likely to characterize the development of the industry over the next few years, said officials and executives during an annual gathering.
HONG KONG – A joint effort by 3SBio Inc. and its new partner Selecta Biosciences Inc. could lead to better treatments for patients with refractory and tophaceous gout. The two companies will work together to combine two products developed independently into one drug that could be distributed globally.
SHANGHAI – Newcomer Ark Biosciences Inc., of Shanghai, has announced its first deal with the acquisition of global rights to Roche AG's respiratory syncytial virus (RSV) drug candidate, AK0529. RSV is one of the most infectious human viruses and the number one cause of death and hospitalization for children younger than 5. There is currently no vaccine or therapeutic drug for RSV infection.
TIANJIN, China – Although the future of stem cell technology is bright, the sector in China has suffered due to a lack of clear regulations, with the then-Ministry of Health suspending clinical research and application of stem cell technology in 2011.
HONG KONG – After decades of trials, blind alleys and false starts, a vaccine for dengue is finally close to market, and patients in Asia may be among the first to benefit from it.
HONG KONG – Just months before the launch of a vaccination campaign, Japan has approved an extended indication for Pfizer Inc.'s pneumococcal conjugate vaccine to cover the elderly.
RSS